Eveglim M 852 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 850mg, designed to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, works by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. This dual-action formulation helps in managing blood sugar levels effectively, especially in patients inadequately controlled by diet and exercise alone or those who require additional therapy beyond monotherapy. Eveglim M 852 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan that includes diet modification, physical activity, and regular monitoring of blood glucose. It is important to take this medication as directed by a healthcare professional to minimize the risk of hypoglycemia and other potential side effects such as gastrointestinal discomfort. Regular follow-up and periodic assessment of renal function are recommended during treatment. This combination tablet offers the convenience of two antidiabetic agents in a single dose, promoting better compliance and overall glycemic control.